Did you know?

ChinaBio® Group is a consulting and advisory firm helping life science companies and investors achieve success in China. ChinaBio works with U.S., European and APAC companies and investors seeking partnerships, acquisitions, novel technologies and funding in China.  

Learn more >>

Free Newsletter

Have the latest stories on China's life science industry delivered to your inbox daily or weekly - free!

  Email address:

China Biologic Products Receives $4.6 Billion Takeover Offer

publication date: Sep 19, 2019

China Biologic Products, a blood products company, received a $4.6 billion takeover offer from a group of six investment firms. The proposal was priced at $120 per share, a 16% premium to the previous close. CBPO operates plasma-gathering facilities (China limits the number of such facilities) and offers 20 plasma-based products. The company is priced at about 30 times trailing earnings. One year ago, CITIC made a $3.9 billion offer for CBPO, which was topped by a syndicate led by a former CEO of the company. CBPO rejected both bids. More details....

Stock Symbol: (NSDQ: CBPO)

Share this with colleagues:

This article is available for purchase - please click here for details.

Sorry this page is available to subscribers only.
If you're not a subscriber why not subscribe today?

If you are already a subscriber, please login.

If you believe you should have received this message in error, please contact us.


To gain access to the members only content click here to subscribe.

You will be given immediate access to premium content on the site.

ChinaBio® News

Greg Scott BIO-Europe Interview
Greg Scott Interviewed at BIO-Europe Spring

How to bring your China assets to China in 8 minutes

Greg Scott Mendelspod Interview
"Mr. Bio in China."
Mendelspod Interview

Multinational pharma held to a higher standard in China

ChinaBio® Events

ChinaBio Partnering Forum 2020

Content Availbalble Until Dec. 21, 2020